reports
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
AVAV AEROVIRONMENT INC.
KFS KINGSWAY FINANCIAL SERVICES
PAYS PAYSIGN INC
PRCH PORCH GROUP INC (A)
SPNT SIRIUSPOINT LTD
MSGE MADISON SQUARE GARDEN ENTERTAINMENT
OSCR OSCAR HEALTH
JOBY JOBY AVIATION INC
COIN COINBASE GLOBAL INC
EVEX EVE HOLDING INC
GCT GIGACLOUD TECHNOLOGY INC
CRBG COREBRIDGE FINANCIAL INC.
SGHC SUPER GROUP (SGHC) LIMITED
RDW REDWIRE CORP
DAVE DAVE INC
GRALV GRAIL INC.
SMCI SUPER MICRO COMPUTER INC.
EVTL VERTICAL AEROSPACE LTD.
ANET ARISTA NETWORKS INC
OWLT OWLET INC
ESP BROMPTON ENERGY SPLIT CORP
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Import...
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia events, particularly in patients with blood glucose ≤55 mg/dL THE WOODLANDS, Texas, June 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) annou...
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
HPP HUDSON PACIFIC PROPERTIES INC.
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
MOD MODINE MANUFACTURING COMPANY
GLP GLOBAL PARTNERS LP
CDXS CODEXIS
BUSE FIRST BUSEY CORPORATION
AMPH AMPHASTAR PHARMACEUTICALS INC
PZG PARAMOUNT GOLD NEVADA CORP.
GIII G-III APPAREL GROUP LTD.
OXM OXFORD INDUSTRIES INC.
CIA CITIZENS INC. CL A
FLL FULL HOUSE RESORTS INC.
ALOT
MLP ASTRONOVA INC.
BCBP MAUI LAND & PINEAPPLE CO. INC.
BRT BCB BANCORP INC.
STKL BRT APARTMENTS
RSSS SUNOPTA
BWB INC.
BHC RESEARCH SOLUTIONS
SONO BRIDGEWATER BANCSHARES
AMPY BAUSCH HEALTH COMPANIES INC.
ENX SONOS
WSC AMPLIFY ENERGY
DLHC EATON VANCE NEW YORK MUNICIPAL BOND FUND
GRNT WILLSCOT MOBILE MINI HOLDINGS CORP
NUVB DALEIGH HOLDINGS CORP
XLO GRANIT SKOPKE
NVCT NUVATION BIO INC (A)
TCBX XILIO THERAPEUTICS INC
BARK NUVECTIS PHARMA INC
OPAL THIRD COAST BANCSHARES INC
GTE ORIGINAL BARK CO
SRM OPAL FUELS INC
MNR GRAN TIERRA ENERGY INC.
SDHC SRM ENTERTAINMENT INC
NCDL MACH NATURAL RESOURCES LP
SUNS SMITH DOUGLAS HOMES CORP
EVM NUVEEN CHURCHILL DIRECT LENDING CORP
LION SUNRISE REALTY TRUST
HYMC EATON VANCE INSD CALIF MUN BD FD
LIONSGATE STUDIOS CORP
HYCROFT MINING HOLDING CORPORATION
- Jonathan Moreland
PZG PARAMOUNT GOLD NEVADA CORP.
GIII G-III APPAREL GROUP LTD.
CIA CITIZENS INC. CL A
RSSS RESEARCH SOLUTIONS
BWB BRIDGEWATER BANCSHARES
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
NUVB NUVATION BIO INC (A)
XLO XILIO THERAPEUTICS INC
EVM EATON VANCE INSD CALIF MUN BD FD
Lexicon to Present Data at the 85th Scientific Sessions of the America...
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) Oral presentation on study demonstrating the ability of sotagliflozin to reduce the risk of hypoglycemic events regardless of kidney function in people with type 1 diabetes THE WOODLANDS, Texas, June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that data from a study evaluating the impact of sotagliflozin on hypoglycemia in people with type 1 diabetes will be delivered as an oral presentation on Sunday, June 22, during the 85th Scientific Sessions of the American Diabetes ...
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Health...
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference THE WOODLANDS, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference, taking place in New York City on Thursday, June 5 at 12:50 p.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering...
- Research Team ACF
GreenRoc Strategic Materials Plc (GROC.L) Core Investment Snapshot 290...
GreenRoc Strategic Materials Plc (AIM: GROC.L) is unusually well positioned to become a key supplier of high-purity, battery-grade graphite into Western markets increasingly focused on critical material security. GROC’s flagship Greenland Amitsoq Graphite Project, has amongst the highest known in-situ graphite grades globally at 20.41% TGC, potential purity is 99.95% (a purity essential to the EV battery value chain looking for lower cost natural graphite vs. synthetic graphite). GROC.L’s Thule ...
ABX. BARRICK GOLD CORPORATION
NOU NOUVEAU MONDE MINING ENTERPRIS
ALBA ALBA MINERAL RESOURCES PLC
SVM SOVEREIGN METALS
SYR SYRAH RESOURCES LIMITED
RIO RIO TINTO PLC
0217127D BHP BILLITON PETROLEUM AMERI
XPEV XPENG INC. ADR SPONSORED CLASS A
LCID LUCID GROUP INC
RIVN RIVIAN AUTOMOTIVE INC
GROC GREENROC MINING PLC
PSNY GORES GUGGENHEIM INC
VFS VINFAST
1884656D ZEEKR
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Co...
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology Lexicon is evaluating the safety and efficacy of sotagliflozin in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) Pivotal Phase 3 clinical trial is actively enrolling patients in 20 countries, with all sites expected to be operational by Q3 2025 THE WOODLANDS, Texas, May 19, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced details of its “SOtaglifloziN in Patients with...
Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results a...
Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into Phase 3 development for diabetic peripheral neuropathic pain Conference call and webcast at 5:00 pm ET THE WOODLANDS, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX), today reported financial re...
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright B...
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on Tuesday, May 20, at 9:30 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexico...
Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results...
Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday, May 13, 2025, after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s website at ...
SiriusPoint reports tenth consecutive quarter of underwriting profits ...
SiriusPoint reports tenth consecutive quarter of underwriting profits and strong net income of $58m HAMILTON, Bermuda, May 05, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE:SPNT) today announced results for its first quarter ended March 31, 2025 Combined ratio of 95.4% in the first quarter for Core business with underwriting income of $29 millionNet premiums written growth of 20%, outpacing gross premiums written growth of 12% in the quarter for Core business, with strong growth from Insurance & ServicesFirst quarter return on equity of 12.9%, within ...
SiriusPoint Announces Dividend on Series B Preference Shares
SiriusPoint Announces Dividend on Series B Preference Shares HAMILTON, Bermuda, May 05, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE: SPNT), an international specialty insurer and reinsurer, has announced that the Audit Committee of the Board of Directors of SiriusPoint Ltd. approved a quarterly cash dividend of $0.50 per share on its 8.00% Resettable Fixed Rate Preference Shares, Series B, $0.10 par value, $25.00 liquidation preference per share payable on or prior to May 30, 2025 to Series B shareholders of record as of May 15, 2025. About SiriusPoin...
SiriusPoint Welcomes AM Best Outlook Revision to ‘Positive’ from ‘Stab...
SiriusPoint Welcomes AM Best Outlook Revision to ‘Positive’ from ‘Stable’ HAMILTON, Bermuda, April 25, 2025 (GLOBE NEWSWIRE) -- AM Best has revised the outlook of the rated operating subsidiaries of SiriusPoint Ltd (“SiriusPoint” or “the Company”) (Bermuda) [NYSE: SPNT] to Positive from Stable, citing the Company’s “very strong balance sheet”. AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a-” (Excellent) of SiriusPoint’s rated operating subsidiaries. Additionally, the rating agency has affirmed the Long-Te...
SiriusPoint Announces Date for First Quarter 2025 Earnings Release
SiriusPoint Announces Date for First Quarter 2025 Earnings Release HAMILTON, Bermuda, April 22, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (NYSE: SPNT) (“SiriusPoint” or the “Company”) today announced that it is planning to release its first quarter 2025 financial results after the market close on Monday, May 5, 2025. The Company will also hold a webcast, which can also be accessed as a conference call, to discuss its financial results at 8:30 am (Eastern Time) on Tuesday May 6, 2025. The webcast of the live conference call can be accessed by logging onto the Investor Relations section of...
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual ...
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual Needham Virtual Healthcare Conference 2025 on Wednesday, April 9, at 8:00 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medici...
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Nov...
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the...
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Heal...
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 THE WOODLANDS, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 in Miami on Wednesday, March 12, at 10:00 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering m...
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Fina...
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on Advancing Strong Pipeline Conference Call and Webcast at 5:00 pm ET THE WOODLANDS, Texas, March 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX), today reported financial results for the three months and year ended December 31, 2024, and provided an update on key corporate m...
Fitch Ratings Revises Outlook on SiriusPoint to Positive Based on Sign...
Fitch Ratings Revises Outlook on SiriusPoint to Positive Based on Significant Underwriting Performance Improvement HAMILTON, Bermuda, March 05, 2025 (GLOBE NEWSWIRE) -- Fitch Ratings (Fitch) has today announced that it has affirmed the ratings of SiriusPoint Ltd. (“SiriusPoint” or the “Company”), including its Long-Term Issuer Default Rating at ‘BBB’, its senior debt rating at ‘BBB-‘ and its Insurer Financial Strength (IFS) rating at ‘A-‘ (Strong) of SiriusPoint’s subsidiaries. It has also revised the Company’s Outlook to Positive from Stable. Fitch said: “The Positive Outlook reflects...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.